Form 4: AnaptysBio Director John A. Orwin Reports Stock Transactions

Director John A. Orwin reports the vesting and disposal of 2,035 shares of AnaptysBio common stock related to restricted stock units.

Summary

• On June 15, 2024, John A. Orwin, a director of AnaptysBio, Inc., reported transactions involving the company's common stock.
• Specifically, 2,035 shares were acquired through the vesting of restricted stock units (RSUs) and simultaneously disposed of.
• The RSUs vested on the date of the Issuer's 2024 annual meeting of shareholders.
• Following the reported transaction, Mr. Orwin directly owns 0 derivative securities.
• The transactions were reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation. It doesn't indicate any particular positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it primarily reflects the vesting of previously granted compensation.

Key Dates